Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 With and Following Rituximab in Patients With Recurrent Indolent and Aggressive Non Hodgkin's Lymphoma
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-07-0815
Full Text
Open PDFAbstract
Available in full text
Date
October 15, 2007
Authors
Publisher
American Association for Cancer Research (AACR)